1. Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study
- Author
-
Dong Jin Chung, Young Sang Lyu, Tae Sun Park, In Joo Kim, Jun Sung Moon, Young Il Kim, Heung Yong Jin, Eonju Jeon, Ju Hyung Lee, Eun Sook Kim, Seung Min Chung, Sang Soo Kim, Sung Woo Kim, Jung Eun Jang, Tae Nyun Kim, Jin Ook Chung, Nan Hee Cho, Sunghwan Suh, Kyu Chang Won, Chang Won Lee, Duk Kyu Kim, Hye Soon Kim, Jeong Mi Kim, Hosang Shon, Min Hee Jang, Sang Yong Kim, Il Seong Nam-Goong, Dong Hyeok Cho, Kyung Ae Lee, Jin Hwa Kim, and Mi-Kyung Kim
- Subjects
Blood Glucose ,Drug ,medicine.medical_specialty ,Combination therapy ,Drug/Regimen ,Endocrinology, Diabetes and Metabolism ,media_common.quotation_subject ,medicine.medical_treatment ,Drug therapy, combination ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Diseases of the endocrine glands. Clinical endocrinology ,Injections ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal medicine ,medicine ,Insulin ,Humans ,Hypoglycemic Agents ,Retrospective Studies ,media_common ,Glycated Hemoglobin ,business.industry ,Type 2 Diabetes Mellitus ,Retrospective cohort study ,RC648-665 ,medicine.disease ,Regimen ,Diabetes Mellitus, Type 2 ,Oral hypoglycemic agents ,Original Article ,business - Abstract
Background Only few studies have shown the efficacy and safety of glucose-control strategies using the quadruple drug combination. Therefore, the aim of the present study was to investigate the usefulness of the quadruple combination therapy with oral hypoglycemic agents (OHAs) in patients with uncontrolled type 2 diabetes mellitus (T2DM). Methods From March 2014 to December 2018, data of patients with T2DM, who were treated with quadruple hypoglycemic medications for over 12 months in 11 hospitals in South Korea, were reviewed retrospectively. We compared glycosylated hemoglobin (HbA1c) levels before and 12 months after quadruple treatment with OHAs. The safety, maintenance rate, and therapeutic patterns after failure of the quadruple therapy were also evaluated. Results In total, 357 patients were enrolled for quadruple OHA therapy, and the baseline HbA1c level was 9.0%±1.3% (74.9±14.1 mmol/mol). After 12 months, 270 patients (75.6%) adhered to the quadruple therapy and HbA1c was significantly reduced from 8.9%±1.2% to 7.8%±1.3% (mean change, −1.1%±1.2%; P
- Published
- 2021